PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
| Autor: | Richard P. Baum, Eric P. Krenning, Mark Kidd, Giovanni Paganelli, Stefano Severi, Anna Malczewska, Irvin M. Modlin, Wouter A. van der Zwan, Ignat Drozdov, Dik J. Kwekkeboom, Aviral Singh, Lisa Bodei |
|---|---|
| Přispěvatelé: | Radiology & Nuclear Medicine |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Neuroendocrine tumors PPQ Tumor response Article NO 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine NETest Biomarkers Tumor Humans Medicine Radiology Nuclear Medicine and imaging Biomarker Liquid biopsy Neuroendocrine PRRT Netherlands business.industry Transcript analysis General Medicine medicine.disease Pancreatic Neoplasms Radiation therapy Neuroendocrine Tumors Italy 030220 oncology & carcinogenesis Radionuclide therapy Biomarker (medicine) business Blood sampling |
| Zdroj: | Eur J Nucl Med Mol Imaging European Journal of Nuclear Medicine and Molecular Imaging, 47, 895-906. Springer-Verlag |
| ISSN: | 1619-7089 1619-7070 |
| Popis: | PURPOSE: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy, NETest monitors disease. We prospectively evaluated: 1) NETest as a surrogate biomarker for RECIST; 2) The correlation of NETest levels with PPQ prediction. METHODS: Three independent (177)Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n=72; Bad-Berka, Germany: n=44; Rotterdam, Netherlands: n=41). Treatment response: RECIST1.1 [Responder (stable, partial and complete response) vs Non-Responder]. Blood sampling: pre-PRRT, before each cycle and follow-up (2-12 months). PPQ (positive/negative) and NETest (0-100 score) by PCR. Stable≤40; progressive >40). CgA (ELISA) as comparator. Samples deidentified, measurement and analyses blinded. Kaplan-Meier survival and standard statistics. RESULTS: 122 of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p40 (progressive) vs stable (≤40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI: 0.02-0.07). PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p97%) with the pretreatment PPQ response predictor. CgA was non-informative. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink